Women Demand Controversial Birth Control Method Be Taken Off the Market
Statement from Bayer:
"Bayer looks forward to an open and transparent discussion regarding Essure at the meeting of the Obstetrics and Gynecology Devices Panel on September 24, 2015. Bayer has been in regular communication with the FDA about the risk-benefit profile of Essure and the informational needs of both healthcare providers and patients.
"Patient safety is Bayer's top priority. Given there has been a great deal of interest in the safety of Essure among some patients, we welcome this open dialogue with healthcare providers, patients, researchers, representatives from professional societies, and other members of the public to review and discuss available data regarding the benefits and risks associated with Essure.
"Bayer is strongly committed to women having access to safe and effective birth control options. The only FDA-approved non-surgical option for women who have completed their families and want permanent contraception, Essure is supported by more than a decade of science and real world clinical experience."